Clinical Trial Search

Primary: Percentage of Recruited Subjects Able to Comply With the Protocol — 12; 13; 3; 14 Participants

Primary: Double Blind (DB) Phase: Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) Score (LOCF) at Week 24 — -2.06; -2.64 score on a…

Primary: Mean Change in Cerebral Blood Flow as Measured by Magnetic Resonance Imaging (MRI) — 0.621528; 0.6447692; 0.654822667; 0.579838667 ml/110g/min

Primary: Functionality in Activities of Daily Living (Changes in Scores Approach) — 0.1; 0; -0.1; -0.2 units on a scale — p=.145

Primary: Change in Alzheimer Disease Assessment Scale-cognitive (ADAS-cog) Score at Week 12 Visit Compared to Baseline — -0.05; -2.25 score on a scale

Primary: Participant Interest in PET Biomarker Disclosure — 73 Participants

Primary: Rate of Change of Hippocampal Volume Slope — -70.2418748; -88.4738591; -94.0768115; -46.9484805 mm^3/year — p=0.095

Primary: Link Between Lack of Word and Presbycusis — 38; 38.5; 23; 21.5 score on a scale

Primary: Regionally Averaged Cerebral Glucose Uptake Changes Measured by FDG PET Uptake With Voxel-based Method — 81.70; 80.40; 84.60; 81.33 Bq/Bq (no unit) — p=0.14

Primary: FCI Score at Follow-up — 147.3; 164.0; 123.3; 150.8 points awarded for correct items

Primary: California Verbal Learning Test II — 6.9; 6.2; 6.46; 5.10 units on a scale — p=0.048

Primary: Word List Memory Total - ADAS-cog — 14.35; 14.7; 15.1; 14.67 Words recalled

Primary: Changes in Dose Response Using the Modified Alzheimer's Disease (AD) Cooperative Study-Clinical Global Impression of Change. — 2; 0; 1; 2 Participants

Primary: Quality of Life in Alzheimer's Disease (QOL-AD)--Participants With Dementia (PWD) — 35.42; 38.10; 35.56; 36.12 score on a scale

Primary: Regional Cerebral Blood Flow Using Arterial Spin-labeling MRI — 55.7; 54.5 mL/g/min — p=0.17

Primary: Change in Quality of Life-Alzheimer's Disease Score — 12.32; 15.88 score on a scale

Primary: Number of Adverse Events — 355; 302 number of AEs

Primary: Evaluations of Behavioral Disorders — 68; 66; 36; 69 Scores on a scale — p=1

Primary: Alpha-synuclein Levels From Nasal Swabs

Primary: Change From Baseline in ADAS-cog+ (Alzheimer's Disease Assesment Scale - Cognitive Subpart) at Week 24 — -10.60; -4.49 points on a scale — p=< 0.0001

Primary: Change in Baseline Burden and Stress of Caregivers Over 3 Months — -52.0; -31.9 percentage change

Primary: Functional Connectivity Scores Between Pairs of Large Scale Brain Networks. — 0.164; 0.374; 0.344; 0.340 connectivity score

Primary: Ratio of Cerebral N Acetyl-Aspartate (NAA) / Cerebral Creatine — 1.49; 1.42 Ratio

Primary: Change From Baseline in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog 14) Score at Week 12 — -1.26; -1.28; -1.68; -1.01 score on a scale — p=0.9819

Primary: Change in East Boston Memory Test Scores From Baseline to 24 Weeks, 48 Weeks, and 72 Weeks — 0.03; -0.02; 0.01; 0.05 score on a scale — p=.409

Primary: Change in Selective Reminding Test - Total Immediate Recall (SRT-IR) — 7.5 units on a scale

Primary: Dispensing of Psychotropic Medications — 161; 315 Participants — p=0.492

Primary: Changes in Prefrontal Cortex Brain Activation at 6 Months — 90.64; -62.20; 28.07; -79.04 beta-weight

Primary: Change in Standardized Uptake Value Ratio (SUVR) of (18F-Florbetapir PET) From Week 0 to Week 52. — 0.07; 0.08 Standardized Uptake Value Ratio

Primary: Change in Connectivity Measure of the TGd Parcellations. — 0.5 abnormal connections